Management is intentionally transitioning 2026 into a 'market preparation' year, prioritizing the upcoming Proteus launch over maximizing near-term Platinum Pro capital sales.

Performance in Q4 2025 was significantly impacted by capital spending headwinds, including NIH funding uncertainties and customer hesitation ahead of the next-generation platform.

The instrument placement program successfully secured 17 new customers, serving as a strategic bridge to maintain user engagement and generate consumable revenue without requiring upfront capital.

Strategic focus has shifted toward building a robust publication pipeline, with 5 manuscripts submitted in 2025 to demonstrate technology utility in clinical proteomics and pathogen detection.

Management pulled forward the Proteus list price announcement to $425,000 to align with academic grant cycles and facilitate long-term capital budgeting for potential customers.

Operational efforts are concentrated on expanding proteome coverage, specifically targeting the detection of 18 to 20 amino acids and increasing sequencing read lengths on the Proteus prototype.

2026 revenue guidance of approximately $1 million reflects a deliberate shift toward consumable utilization and service revenue rather than new hardware sales.

The Proteus commercial launch remains on track for the end of 2026, with prototype systems currently deployed for internal R&D and manufacturing scale-up underway.

Financial guidance assumes a total cash usage of $93 million or less, supported by a balance sheet intended to fund operations into the second quarter of 2028.

Management expects a 25% increase in consumable kit volume in 2026 as the installed base matures and new placement-program users begin running experiments.

Future margin expansion is predicated on the Proteus passive nano-well architecture, which is expected to be significantly more cost-effective to produce than current CMOS-based chips.

Full-year 2025 GAAP expenses included $18.7 million in one-time charges related to a facility lease termination in Connecticut and legacy litigation settlements.

Revenue recognition in the near term may be further suppressed by 'upgrade credits' offered to Platinum Pro buyers to incentivize early adoption of the future Proteus system.

The company maintains high insider ownership and noted that recent management share sales were strictly for mandated tax withholdings related to equity vesting.

Management identified a potential risk in the timing of hardware integration and manufacturing quality control, though they believe the primary 'invention' risk is now resolved.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management expects very modest capital equipment revenue in 2026, with the majority of the $1 million guidance coming from consumables and services.

Despite low hardware sales, they project a 25% increase in the number of consumable kits run by the existing installed base.

The $425,000 price point was released early to ensure the platform is included in upcoming academic grant applications and international tenders.

Management believes this price captures premium value while remaining significantly more accessible than high-end mass spectrometry systems that can exceed $1 million.

The company is progressing ahead of schedule on its goal to detect 18 amino acids at launch and all 20 shortly thereafter.

R&D teams are now specifically dedicated to maximizing sequencing read length to unlock high-value applications like deep post-translational modification (PTM) profiling.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.